Patents by Inventor Yvonne Tay

Yvonne Tay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Micro-RNA inhibitors and their uses in disease
    Patent number: 11274301
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oligonucleotides, including locked nucleic acids (LNAs).
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: March 15, 2022
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
  • COMPOUNDS THAT TARGET MYC microRNA RESPONSIVE ELEMENTS FOR THE TREATMENT OF MYC-ASSOCIATED CANCER
    Publication number: 20200140859
    Abstract: Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
    Type: Application
    Filed: September 4, 2019
    Publication date: May 7, 2020
    Inventors: Pier Paolo Pandolfi, Assaf C. Bester, Yvonne Tay
  • Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
    Patent number: 10443055
    Abstract: Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 15, 2019
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Assaf C. Bester, Yvonne Tay
  • Micro-RNA inhibitors and their uses in disease
    Patent number: 10131905
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: November 20, 2018
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
  • COMPOUNDS THAT TARGET MYC microRNA RESPONSIVE ELEMENTS FOR THE TREATMENT OF MYC-ASSOCIATED CANCER
    Publication number: 20180195067
    Abstract: Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
    Type: Application
    Filed: December 18, 2017
    Publication date: July 12, 2018
    Inventors: Pier Paolo Pandolfi, Assaf C. Bester, Yvonne Tay
  • Micro-RNA Inhibitors and Their Uses in Disease
    Publication number: 20180073025
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
  • MICRO-RNA INHIBITORS AND THEIR USES IN DISEASE
    Publication number: 20150126579
    Abstract: The invention relates to the treatment and prevention of cancer by administering agents that inhibit the activity of microRNAs that modulate tumor suppressor genes, which can include PTEN, p53, and INPP4B, among others. Inhibitors can include oligonucleotides that are at least partially complementary to these miRNAs. In some embodiments, these inhibitors are chemically modified oliognucleotides, including locked nucleic acids (LNAs).
    Type: Application
    Filed: April 12, 2012
    Publication date: May 7, 2015
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Pier Paolo Pandolfi, Laura Poliseno, Yvonne Tay, Leonardo Salmena
  • MUTEINS OF THE BACTERIOPHAGE LAMBDA INTEGRASES
    Publication number: 20130017578
    Abstract: The present invention refers to muteins of the bacteriophage lambda integrases and to nucleic acid molecules comprising a nucleotide sequence encoding such muteins of the lambda integrases. The invention further refers to host cells containing a nucleic acid molecule comprising a nucleotide sequence encoding such muteins of the lambda integrases. The invention also refers to methods of recombining nucleic acids of interest into target nucleic acids in the presence of the muteins of the lambda integrases, as well as sequence specific recombination kits.
    Type: Application
    Filed: November 8, 2010
    Publication date: January 17, 2013
    Inventors: Farid John Ghadessy, Mei Sian Yvonne Tay, Peter Drodge